ONCR
Price:
$0.1205
Market Cap:
$0
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability ...[Read more]
Industry
Biotechnology
IPO Date
2020-10-02
Stock Exchange
NASDAQ
Ticker
ONCR
According to Oncorus, Inc.’s latest financial reports and current stock price. The company's current ROE is -82.19%. This represents a change of 75.49% compared to the average of -46.84% of the last 4 quarters.
The mean historical ROE of Oncorus, Inc. over the last ten years is -25.64%. The current -82.19% ROE has changed 220.54% with respect to the historical average. Over the past ten years (40 quarters), ONCR's ROE was at its highest in in the September 2020 quarter at 16.52%. The ROE was at its lowest in in the March 2023 quarter at -106.97%.
Average
-25.64%
Median
-34.74%
Minimum
-129.38%
Maximum
45.03%
Discovering the peaks and valleys of Oncorus, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 160.02%
Maximum Annual ROE = 45.03%
Minimum Annual Increase = -185.48%
Minimum Annual ROE = -129.38%
Year | ROE | Change |
---|---|---|
2022 | -129.38% | 160.02% |
2021 | -49.76% | 43.23% |
2020 | -34.74% | -185.48% |
2019 | 40.64% | -9.74% |
The current ROE of Oncorus, Inc. (ONCR) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-71.29%
5-year avg
-25.64%
10-year avg
-25.64%
Oncorus, Inc.’s ROE is less than eFFECTOR Therapeutics, Inc. (0%), less than Apollomics, Inc. (2.18%), greater than Angion Biomedica Corp. (-184.11%), greater than Sigilon Therapeutics, Inc. (-98.89%), greater than Pyxis Oncology, Inc. (-74.73%), greater than Zura Bio Limited (-36.23%), greater than Altamira Therapeutics Ltd. (-39.61%), less than Elevation Oncology, Inc. (783.37%), greater than Landos Biopharma, Inc. (-59.73%), greater than Apexigen, Inc. (-73.00%), less than Cardio Diagnostics Holdings, Inc. (48.27%), greater than null (-258.81%),
Company | ROE | Market cap |
---|---|---|
0% | $941.00 | |
2.18% | $9.98M | |
-184.11% | $30.11M | |
-98.89% | $56.22M | |
-74.73% | $112.90M | |
-36.23% | $178.25M | |
-39.61% | $1.60M | |
783.37% | $35.67M | |
-59.73% | $71.68M | |
-73.00% | $9.57M | |
48.27% | $10.73M | |
-258.81% | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Oncorus, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Oncorus, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Oncorus, Inc.'s ROE?
How is the ROE calculated for Oncorus, Inc. (ONCR)?
What is the highest ROE for Oncorus, Inc. (ONCR)?
What is the 3-year average ROE for Oncorus, Inc. (ONCR)?
What is the 5-year average ROE for Oncorus, Inc. (ONCR)?
How does the current ROE for Oncorus, Inc. (ONCR) compare to its historical average?